Literature DB >> 18242346

Red blood cell arginase suppresses Jurkat (T cell) proliferation by depleting arginine.

Andrew Bernard1, Michael Kasten, Cindy Meier, Erin Manning, Stephanie Freeman, Will Adams, Phillip Chang, Bernard Boulanger, Paul Kearney.   

Abstract

BACKGROUND: Transfusion of packed red blood cells (PRBC) suppresses immunity, but the mechanisms are incompletely understood. PRBCs contain arginase, an enzyme which converts arginine to ornithine and depletes arginine in vitro. Arginine depletion suppresses proliferation of Jurkat T cells in other models. We hypothesize that PRBC arginase-mediated arginine depletion will suppress proliferation of T cells.
METHODS: A transfusion model was designed adding PRBC to culture RPMI media with or without an irreversible arginase blocker (nor-NOHA), incubating for 6-48 hours and then removing the PRBCs. Amino acid concentrations in the media were measured using liquid chromatography mass spectrometry. T cells were then added to the pre-conditioned media, cultured for 24 hours, and proliferation was measured.
RESULTS: PRBC depleted arginine significantly and increased ornithine in media compared to baseline PRBC treated wells and significantly decreased T cell proliferation. These effects were enhanced with volume of PRBC exposure. Nor-NOHA inhibition of arginase restored T cell proliferation in PRBC treated cultures.
CONCLUSIONS: Jurkat T cell proliferation was impaired by PRBC in clinically relevant volumes. The mechanism influencing T cell impairment appears to result from arginine depletion by arginase. Arginine depletion by PRBC arginase may be a novel mechanism for immunosuppression after transfusion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18242346     DOI: 10.1016/j.surg.2007.07.037

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  A role for IL-18 in protective immunity against Mycobacterium tuberculosis.

Authors:  Bianca E Schneider; Daniel Korbel; Kristine Hagens; Markus Koch; Bärbel Raupach; Jana Enders; Stefan H E Kaufmann; Hans-Willi Mittrücker; Ulrich E Schaible
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

Review 2.  Arginase: an emerging key player in the mammalian immune system.

Authors:  Markus Munder
Journal:  Br J Pharmacol       Date:  2009-09-17       Impact factor: 8.739

3.  L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure.

Authors:  Thorsten Brenner; Thomas H Fleming; Claudia Rosenhagen; Ute Krauser; Markus Mieth; Thomas Bruckner; Eike Martin; Peter P Nawroth; Markus A Weigand; Angelika Bierhaus; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2012-05-06       Impact factor: 4.711

Review 4.  Arginine depletion increases susceptibility to serious infections in preterm newborns.

Authors:  Shiraz Badurdeen; Musa Mulongo; James A Berkley
Journal:  Pediatr Res       Date:  2014-10-31       Impact factor: 3.756

5.  Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.

Authors:  Susanne M Steggerda; Mark K Bennett; Jason Chen; Ethan Emberley; Tony Huang; Julie R Janes; Weiqun Li; Andrew L MacKinnon; Amani Makkouk; Gisele Marguier; Peter J Murray; Silinda Neou; Alison Pan; Francesco Parlati; Mirna L M Rodriguez; Lee-Ann Van de Velde; Tracy Wang; Melissa Works; Jing Zhang; Winter Zhang; Matthew I Gross
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

6.  Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma.

Authors:  David J Tate; Derek J Vonderhaar; Yupanqui A Caldas; Toye Metoyer; John R Patterson; Diego H Aviles; Arnold H Zea
Journal:  J Hematol Oncol       Date:  2008-09-25       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.